SGHT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sight Sciences Inc (SGHT) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has mixed signals with bearish technical indicators, insider selling, and weak financial performance. While there are positive catalysts like the recent court ruling in favor of SGHT and some bullish analyst ratings, the overall sentiment and trends do not strongly support an immediate buy decision.
The technical indicators show a bearish trend with moving averages in a negative alignment (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 32.853, and the MACD is slightly positive but contracting. The stock is trading near its support level of 3.489, indicating potential downside risk.
This provides a potential revenue stream and strengthens the company's IP position. Additionally, some analysts maintain a Buy rating, citing optimism around the TearCare opportunity and the surgical glaucoma business.
Insiders are selling heavily, with a 4122.05% increase in selling activity over the last month, which could indicate a lack of confidence in the stock's near-term prospects. The company's financial performance in Q4 2025 showed a significant decline in net income (-64.87% YoY) and EPS (-65.22% YoY), despite a modest revenue increase. The bearish technical indicators and lack of recent Congress trading data further weaken the case for an immediate buy.
In Q4 2025, Sight Sciences reported a 6.87% YoY increase in revenue to $20.39 million. However, net income dropped significantly by 64.87% YoY to -$4.16 million, and EPS fell by 65.22% YoY to -$0.08. Gross margin improved slightly to 87.26%, up 0.50% YoY, but overall financial performance remains weak.
Analyst sentiment is mixed. UBS maintains a Buy rating with a price target of $11, citing strong performance in Dry Eye but weaker trends in Surgical Glaucoma. Stifel raised its price target to $8 from $6 with a Buy rating, while Citi lowered its target to $5 from $6.50 and maintains a Neutral rating. Piper Sandler upgraded the stock to Overweight with a $9 price target, citing optimism around TearCare and better-than-expected performance in the surgical glaucoma business.
